The most recent filing that the company made with the Securities and Exchange Commission (SEC) revealed that during the third quarter, UBS Group AG increased the percentage of USANA Health Sciences, INC (NYSE: USNA) shares that it owned by 51.8%.
The fund finished the time frame with a total holding of 87,250 shares of the company’s stock, which was achieved by purchasing an additional 29,755 shares during the time frame. UBS Group AG had a 0.45% stake in USANA Health Sciences as of the end of the most recent quarter, worth $4,890,000.
Several institutional investors and hedge funds have changed the positions they currently hold in USNA in recent weeks.
During the first quarter of the fiscal year, Vanguard Group INC bought an additional 0.8% of the shares in USANA Health Sciences. Vanguard Group INC now has 1,510,852 shares after purchasing an additional 12,121 in the most recent fiscal quarter.
The value of these shares comes to $120,037,000.
During the second quarter, Renaissance Technologies LLC completed an increase in its ownership stake in USANA Health Sciences, equal to a 0.5% increase.
After acquiring a further 7,534 shares during the most recent period, Renaissance Technologies LLC now owns 1,431,797 shares of the company.
The value of these shares brings the company’s overall holdings to $103,605,000.
During the first three months of 2018, Dimensional Fund Advisors LP amassed an additional 0.4% of USANA Health Sciences stock, bringing the total percentage of its shares to 100%.
Dimensional Fund Advisors LP now has 566,420 shares after purchasing an additional 2,390 shares during the most recent period.
The value of Dimensional Fund Advisors LP’s entire holding in the company is a combined total of $45,002,000. State Street Corporation purchased a further 1.8% stake in USANA Health Sciences during the first three months of 2018. State Street Corp. now has 386,877 shares of the company’s stock, currently valued at $30,730,000, after purchasing an additional 6,817 shares during the period in question.
And finally, during the first three months of this year, Invesco Ltd added three percent more shares of USANA Health Sciences to its holdings, bringing the total to twenty-five.
Invesco Ltd now has 159,705 shares after purchasing an additional 4,604 in the most recent period.
The company’s stock currently stands at a total of $12,688,000. Currently, 52.62% of the company’s shares are owned by hedge funds and other institutional investors.
When trading started on Wednesday, a share of USANA Health Sciences was $60.78.
The company’s market capitalization is currently valued at $1.17 billion, its PE ratio is 16.93, and its beta is 0.73.
The current value of the company’s beta is 0.73.
The company’s moving average price over the previous 50 days is $57.68, and the moving average price over the previous 200 days is $57.78. USANA Health Sciences, INC reached a 52-week low of $48.51, while the company reached a 52-week high of $90.29 during this period.
On February 7, the most recent earnings report for USANA Health Sciences was made public.
This company’s shares are traded on the New York Stock Exchange under the symbol USNA.
The company reported quarterly earnings per share at $0.66, $0.31 higher than the consensus estimate of $0.35 from industry analysts.
As can be seen, by their net margin of 6.94% and their return on equity of 16.92%, USANA Health Sciences had a very successful year financially.
The company reported total revenues of $227.96 million in the period in question.
The company’s earnings per share came in at $1.0, comparable to the results achieved during the same period in the previous year.
Experts in the field of research have projected that USANA Health Sciences, INC will achieve earnings of $2.85 per share in 2018.
The company has received responses from several equity analysts, which were sent to the company. On Monday, February 13, DA Davidson published a research note that raised their price objective for USANA Health Sciences from $49.00 to $52.50 and gave the stock a “neutral” rating.
The note also stated that they maintained their “underweight” rating for the stock.
The report came out the very same day it was written. StockNews.com downgraded its recommendation for USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report published on Thursday, February 16.
According to reports from other news outlets, on February 9, a company insider named Brent Neidig sold 1,872 shares of the company’s stock.
The stock was sold for a total value of 115,858.08 dollars, which works out to a price of $61.89 per share on average. Following the successful transaction completion, the company insider will now directly own 2,435 shares of the company’s stock, each of which has a value of $150,702.15, bringing the total value of the insider’s stock holdings to $150,702.15. Follow the link, which will take you to a filing submitted to the Securities and Exchange Commission. You will have the opportunity to acquire additional information regarding the transaction.
According to reports from other USANA Health Sciences news outlets, on February 16, an employee of the company named Joshua Foukas sold 3,771 shares of the company’s stock.
The stock was sold for a total value of $230,068.71, with each share fetching an average price of $61.01 and the transaction totaling $230,068.71.
As a direct result of the transaction, the insider now owns 3,012 company shares, with a combined value of approximately 183,762.12 dollars.
Additional information regarding the transaction can be found in a document sent to the SEC and is now available online.
Another company insider, Brent Neidig, sold a total of 1,872 shares of the company’s stock on the trading day of Thursday, February 9.
The stock was sold for a total value of 115,858.08 dollars, which works out to a price of $61.89 per share on average.
After the completion of the transaction, the insider now directly owns 2,435 shares of the company.
These shares are $150,702.15, making them a significant investment.
Disclosures related to the sale might be found in this website section. Corporate insiders sold 20,809 shares of company stock during the most recent ninety days for a total value of $1,251,393, which represents 0.36% of the total number of currently outstanding shares.
USANA Health Sciences, INC is a company that specializes in the research, development, and marketing of products for nutrition, personal care, and weight management.
These categories include weight management, personal care, and nutrition. USANA Nutritionals, USANA Foods, Personal Care & Skincare, and All Other are the four distinct business divisions that the company operates under.
The company was founded in 1982 and is headquartered in Utah.
This company is responsible for producing several brands; Procosa and MagneCal D.
Myron W. went into business for himself and started it from the ground up.